(NASDAQ: INDV) Indivior Pharmaceuticals's forecast annual revenue growth rate of 2.64% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.57%.
Indivior Pharmaceuticals's revenue in 2026 is $1,291,000,000.On average, 8 Wall Street analysts forecast INDV's revenue for 2026 to be $154,841,013,660, with the lowest INDV revenue forecast at $138,259,613,772, and the highest INDV revenue forecast at $164,594,778,300. On average, 8 Wall Street analysts forecast INDV's revenue for 2027 to be $162,278,259,198, with the lowest INDV revenue forecast at $146,184,547,542, and the highest INDV revenue forecast at $171,788,179,722.
In 2028, INDV is forecast to generate $170,325,115,026 in revenue, with the lowest revenue forecast at $155,938,312,182 and the highest revenue forecast at $183,736,541,406.